Orforglipron

Orforglipron is a new weight management medication that works similarly to GLP-1 drugs like semaglutide but comes in a convenient daily pill form instead of an injection. It helps control appetite and blood sugar by mimicking natural hormones that regulate hunger. This medication is currently being studied in clinical trials and represents an exciting advance in non-injectable weight loss options.

Orforglipron is a non-peptide, oral GLP-1 receptor agonist with a biased signalling profile that preferentially activates cAMP over β-arrestin pathways. Unlike peptide-based GLP-1 agonists such as semaglutide and liraglutide, its small-molecule structure confers oral bioavailability without absorption enhancers. Phase 2 clinical trials demonstrated dose-dependent weight loss of up to 14.7% of body weight at 36 weeks, with a safety profile comparable to injectable GLP-1 agents.

An effective oral GLP-1 agonist could significantly expand access to medical weight loss therapy, particularly for patients with needle phobia or those who prefer pill-based treatment. Dr. Joseph Wang at Accord Medical Clinic monitors emerging pharmacotherapies like orforglipron to offer patients the most current weight management options.